Styliani Vakrou

Dr. Styliani Vakrou

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
SVStyliani Vakrou
Styliani Vakrou
RFRyuya Fukunaga
Ryuya Fukunaga
DFD. Brian Brian Foster
D. Brian Brian Foster
LSLars Sorensen
Lars Sorensen
YLYamin Liu
Yamin Liu
MAM. Roselle Abraham
M. Roselle Abraham
Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation–bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti–TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.

6 December 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
DADimitra Aravani
Dimitra Aravani
EKEva Kassi
Eva Kassi
ACAntonios Chatzigeorgiou
Antonios Chatzigeorgiou
SVStyliani Vakrou
Styliani Vakrou
Cardiometabolic syndrome (CMS), a disease entity characterized by abdominal obesity, insulin resistance (IR), hypertension, and hyperlipidemia, is a global epidemic with approximately 25% prevalence in adults globally. CMS is associated with increased risk for cardiovascular disease (CVD) and development of diabetes. Due to its multifactorial etiology, the development of several animal models to simulate CMS has contributed significantly to the elucidation of the disease pathophysiology and the design of therapies. In this review we aimed to present the most common mouse models used in the research of CMS. We found that CMS can be induced either by genetic manipulation, leading to dyslipidemia, lipodystrophy, obesity and IR, or obesity and hypertension, or by administration of specific diets and drugs. In the last decade, the ob/ob and db/db mice were the most common obesity and IR models, whereas Ldlr−/− and Apoe−/− were widely used to induce hyperlipidemia. These mice have been used either as a single transgenic or combined with a different background with or without diet treatment. High-fat diet with modifications is the preferred protocol, generally leading to increased body weight, hyperlipidemia, and IR. A plethora of genetically engineered mouse models, diets, drugs, or synthetic compounds that are available have advanced the understanding of CMS. However, each researcher should carefully select the most appropriate model and validate its consistency. It is important to consider the differences between strains of the same animal species, different animals, and most importantly differences to human when translating results. * These authors contributed equally to this work as senior authors. Received: 03 June 2020 Accepted: 24 October 2020 Publication Date: 06 December 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

15 July 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
SVStyliani Vakrou
Styliani Vakrou
CVCharalampos Vlachopoulos
Charalampos Vlachopoulos
Konstantinos A. GatzoulisKonstantinos A. Gatzoulis
Konstantinos A. Gatzoulis
Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um [...] Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um

17 March 2026 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
Alexios S AntonopoulosAlexios S Antonopoulos
Alexios S Antonopoulos
TTTheodoros Tsampras
Theodoros Tsampras
Panagiotis F. KanatasPanagiotis F. Kanatas
Panagiotis F. Kanatas
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
MKMaria Koutelou
Maria Koutelou
SVSofia Vaina
Sofia Vaina
Transthyretin cardiac amyloidosis (ATTR) is prevalent among patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS). We aimed to develop and validate a risk score for predicting ATTR in this context. In the prospective multicentre GRECA-TAVI registry, 500 patients with severe AS scheduled for TAVI were screened for ATTR using technetium-99m-labeled DPD or PYP bone scintigraphy in 12 tertiary hospitals, from January 1st to December 31st, 2024. Clinical, echocardiographic, and electrocardiographic variables were recorded. A logistic regression-derived integer-based risk score was developed in a training cohort (n=350) and validated in a validation cohort (n=150). Model performance was evaluated using discrimination, calibration, and decision curve analyses. ATTR was diagnosed in 38 patients (7.6%). Five variables (age, sex, MWT, LVEF, and intracardiac device presence) formed the basis of an 8-point risk score. The score demonstrated good discrimination (AUC=0.75 training, 0.76 validation) and calibration (slope=1.15). A score ≥4 identified patients with a ∼16% ATTR prevalence compared to 2.4% in those with a score <4. This threshold captured most of the ATTR cases (73%) while recommending screening for only 36% of the cohort. Decision curve analysis showed net clinical benefit across clinically relevant thresholds (5-20%) over and above a guideline-recommended approach (based on MWT≥12mm) or a screen-all strategy. ATTR is common in patients with severe AS undergoing TAVI. A simple bedside score using routinely available variables effectively identifies those patients at risk for ATTR. Selective screening using this tool could improve diagnostic yield and resource allocation.

10 March 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
Despina SanoudouDespina Sanoudou
Despina Sanoudou
SVStyliani Vakrou
Styliani Vakrou
AFAlexandra Frogoudaki
Alexandra Frogoudaki

4 October 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
NVNikolaos Vasileiou
Nikolaos Vasileiou
IKIoannis Kouris
Ioannis Kouris
Ioannis KakkosIoannis Kakkos
Ioannis Kakkos
Lefteris KoumakisLefteris Koumakis
Lefteris Koumakis
MKMiltiadis Kokkonidis
Miltiadis Kokkonidis
George K. MatsopoulosGeorge K. Matsopoulos
George K. Matsopoulos
Digital health solutions increasingly rely on interoperable software platforms that integrate heterogeneous data sources, support remote patient monitoring and deliver clinical decision support while complying with strict security, privacy and regulatory requirements. Numerous studies report the clinical outcomes or analytical capabilities of such systems. However, the engineering processes leading to their development are rarely described in a systematic manner. This paper presents the design, development, integration and technical validation of the RETENTION digital health platform for the remote monitoring and management of advanced heart failure patients. The platform was developed as a modular software ecosystem integrating mobile and web applications, medical devices, clinical and real-world data repositories, and artificial intelligence services through an HL7 FHIR-centred architecture. The complete engineering lifecycle, from requirements and architecture to software development, integration and validation, is described in this paper. Emphasis is placed on the adoption of interoperability standards, Security and Privacy by Design principles, data management mechanisms and deployment strategies that enable the integration of heterogeneous technologies into a unified platform. By documenting the complete development pathway, this work aims to serve as a guide for the design and implementation of large-scale digital health platforms that support remote patient monitoring and chronic disease management.